News | Heart Failure | June 30, 2016

BioVentrix Receives CE Marking Certification for Revivent TC Heart Failure System

Device enables the treatment and management of patients who suffered a myocardial infarction resulting in left ventricular dysfunction

BioVentrix, Revivent-TC, transcatheter heart failure system, CE Mark

June 30, 2016 — BioVentrix Inc. announced that it has received certification for CE marking its Revivent TC TransCatheter Ventricular Enhancement System. Following a myocardial infarction or heart attack, the Revivent TC System implants proprietary micro-anchor pairs to exclude scarred myocardium from the healthy tissue of the left ventricle (LV). The restoration of the LV to a more optimal volume and conical shape has proven to enhance cardiac performance and significantly improve a patient's quality of life1.

At two-year follow-up, patients have made remarkable improvements in their quality of life by 38 percent, according to BioVentrix. Additionally, the clinical benefit has been proven to extend life for patients with a significant reduction of LV end-systolic volume index (31 percent) and improvement of LV ejection fraction (23 percent)2. Left ventricular volume reduction is especially critical for the survival of a patient as other studies have shown that significant LV volume reduction can directly prolong a patient's life1. According to the company, the Revivent TC System is the only interventional therapy that can consistently achieve this survival benefit in heart failure patients. 

References

1. Michler R et al. Insights from the STICH trial: Change in left ventricular size after coronary artery bypass grafting with and without surgical ventricular reconstruction. J of Thoracic and Cardiovascular Surgery. 29 October 2012 (10.1016/j.jtcvs.2012.09.007).

2. Data available on file.

3. Wechsler, A. et al., Clinical benefits twelve months after less invasive ventricular restoration operations without ventriculotomy. Annual meeting of the European Society of Cardio-Thoracic Surgery, 07 Oct. 2013, Vienna, Austria.


Related Content

News | Heart Failure

July 14, 2025 — Bayer has announced that the U.S. Food and Drug Administration (FDA) approved KERENDIA (finerenone) to ...

Home July 14, 2025
Home
News | Heart Failure

June 23, 2025 — iRhythm Technologies, Inc. announced the results from two large-scale real-world studies presented at ...

Home June 25, 2025
Home
News | Heart Failure

June 3, 2025 — Bayer announced it will present multiple new analyses of the Kerendia (finerenone) clinical trial program ...

Home June 04, 2025
Home
News | Heart Failure

March 25, 2025 — Bayer plans to present data from 13 new analyses from across the KERENDIA (finerenone) comprehensive ...

Home March 25, 2025
Home
News | Heart Failure

March 17, 2025 — Bayer recently announced that the U.S. Food and Drug Administration (FDA) accepted its supplemental new ...

Home March 21, 2025
Home
News | Heart Failure

Jan. 7, 2025 — FIRE1 recently announced it has received Breakthrough Device Designation from the U.S. Food and Drug ...

Home January 07, 2025
Home
News | Heart Failure

Heart failure is a rapidly growing public health issue that can be difficult to manage on a global scale. But there are ...

Home October 02, 2024
Home
News | Heart Failure

Sept. 30, 2024 — Cytokinetics, Inc. recently announced that additional analyses synthesizing data from SEQUOIA-HCM ...

Home October 02, 2024
Home
News | Heart Failure

Sept. 18, 2024 – Astellas Pharma Inc. recently announced that Digitiva, a non-invasive digital health solution for heart ...

Home September 19, 2024
Home
News | Heart Failure

Aug. 21, 2024 — The incidence rate of heart failure was 2- to 3-fold higher among American Indian populations than rates ...

Home August 21, 2024
Home
Subscribe Now